Key Points
- CEO Adam Schechter sold 5,903 Labcorp shares on Monday, May 11, at an average price of $254.50, totaling about $1.5 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Labcorp’s latest earnings beat expectations, with quarterly EPS of $4.25 versus the $4.09 consensus and revenue of $3.54 billion, up 5.8% year over year. The company also reiterated FY 2026 guidance of 17.7 to 18.35 EPS.
- The company announced a quarterly dividend of $0.72 per share, payable June 11 to shareholders of record on May 29. That works out to an annualized dividend of $2.88 and a yield of about 1.1%.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) CEO Adam Schechter sold 5,903 shares of Labcorp stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares of the company's stock, valued at $27,291,053. This trade represents a 5.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Labcorp Stock Down 1.1%
LH opened at $254.40 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The stock has a market capitalization of $20.86 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 1.80 and a beta of 0.91. The business has a 50-day moving average of $266.53 and a two-hundred day moving average of $265.91. Labcorp Holdings Inc. has a 12 month low of $239.67 and a 12 month high of $293.72.
Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts expect that Labcorp Holdings Inc. will post 17.99 earnings per share for the current year.
Labcorp Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp's payout ratio is 25.51%.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on LH. Piper Sandler lifted their price objective on Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, February 24th. Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a research note on Saturday, May 2nd. Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a research note on Tuesday, February 17th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Robert W. Baird set a $334.00 price objective on Labcorp in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Labcorp presently has a consensus rating of "Moderate Buy" and a consensus price target of $308.00.
Check Out Our Latest Research Report on LH
Hedge Funds Weigh In On Labcorp
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPL Wealth Management LLC acquired a new position in Labcorp during the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Labcorp during the 4th quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in Labcorp during the 4th quarter worth approximately $27,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the 4th quarter worth approximately $29,000. Finally, DV Equities LLC acquired a new position in Labcorp during the 4th quarter worth approximately $29,000. 95.94% of the stock is owned by institutional investors and hedge funds.
Labcorp Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
